Paul Lundquist joined MGI as vice president of Engineering in 2018. He holds a Ph.D. in Physics from Northwestern University. Dr. Lundquist started out doing basic research at the IBM-Almaden Research Center and moved from there to early-stage startups. He was the first engineer at Pacific Biosciences. Moving from a novel idea to commercial success takes deep expertise in very disparate fields, integrating the expertise of outsiders, and a willingness to continually adapt, he said. MGI is an e...

What are the advantages of automated library construction compared to manual one? We used the MGISP-100 automated sample preparation system to conduct a competition: Clinical application case At the same time, three kinds of fertility tests such as NIPT, PGS and CNV were carried out, and the weekly throughput was 96 cases. Laboratory configuration: "MGISP-100 can realize a variety of uses on one machine. It's easy to operate, and can be used after 2 days of simple training so that we can giv...

Have you thought about a question, why do we need to constantly improve the sequencing throughput? Do you know how much data each living body means? Today, we look at the development of astronomy, maybe there will be a new understanding to this problem. Exploring the Universe: A Century of Astronomy In the Age of Enlightenment in which Newton was in, human beings observed new phenomena through new tools and methods, established new theories, and brought new ways of producing and living and n...

Complete Genomics, a U.S. affiliate of MGI, has filed a patent infringement counterclaim against Illumina in U.S. District Court for the Northern District of California. The lawsuit, filed September 30, alleges that Illumina and its customers are using various gene sequencers and related reagents, including NovaSeq 6000, HiSeq X Ten, HiSeq 3000, and HiSeq 4000, that infringe Complete Genomics’ U.S. Patent No. 9,944,984 ("984 patent"). The patent covers MGI's proprietary Patterned Array technol...

Therefore, the manufacturer of the sequencer is in the absolute upstream of the genetic testing industry, the midstream is the company that provides genetic testing services to users, and the downstream is the user groups such as hospitals, scientific research institutions, and consumers. Previously, the production of the sequencer had been monopolized by two American companies, Illumina and Thermo Fisher. The consequence of this is that the bargaining power of genetic testing companies in the ...

Introduction Dr. Radoje (Rade) Drmanac, chief scientific officer and co-founder of Complete Genomics, is a research scientist and inventor in the field of human genome sequencing, including techniques such as DNA sequencing-by-hybridization (SBH), genomic micro- and nanoarrays, combinatorial probe ligation, and long fragment read (LFR) process for accurate whole genome sequencing and haplotyping from 10 human cells. In 1994, he co-founded Hyseq (later Nuvelo) where, as chief scientific officer,...